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S U M M A R Y
Objectives: French Polynesia is a high epidemic/endemic area for arthropod-borne viruses (arboviruses).
We recently reported the silent circulation of Ross River virus and absence of active transmission of
chikungunya virus (CHIKV) among blood donors sampled before the emergence of Zika virus (ZIKV) and
CHIKV in French Polynesia. In this study, the prevalence of the four serotypes of dengue virus (DENV) and
the occurrence of circulation of other arboviruses were investigated in blood donors in French Polynesia.
Methods: Serum samples from 593 blood donors collected between July 2011 and October 2013 were
tested by ELISA for the presence of immunoglobulin G antibodies against each of the four DENV
serotypes, ZIKV, Japanese encephalitis virus (JEV), and West Nile virus (WNV).
Results: It was found that 80.3%, 0.8%, 1.3%, and 1.5% of blood donors were seropositive for at least one
DENV serotype, ZIKV, JEV, and WNV, respectively.
Conclusions: These results corroborate the expected high transmission of DENV and conversely suggest
that no active circulation of ZIKV, JEV, and WNV occurred in French Polynesia before 2011. Information
provided by this study may be useful for public health authorities to improve surveillance and
implement strategies to prevent the transmission of arboviruses.
 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
French Polynesia, a French overseas territory in the South
Paciﬁc, is a high epidemic/endemic area for arthropod-borne
viruses (arboviruses). The four serotypes of dengue virus (DENV)
have caused several outbreaks since the 1940s.1 Zika virus (ZIKV)
and chikungunya virus (CHIKV) emerged in October 20132 and
October 2014,3 respectively.
Different arbovirus infections can have similar clinical pre-
sentations, and their circulation may be underreported if speciﬁc
diagnostic tools have not been implemented. We recently
described the silent circulation of Ross River virus (RRV) and the
absence of active CHIKV transmission before the CHIKV outbreak in* Corresponding author. Tel./Fax: +689 40 416 460/+689 40 431 590.
E-mail address: maubry@ilm.pf (M. Aubry).
http://dx.doi.org/10.1016/j.ijid.2015.10.005
1201-9712/ 2015 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).French Polynesia.4 In the present study, the seroprevalence of each
DENV serotype and the possible circulation of other undetected
arboviruses were investigated among the same population of
blood donors.
2. Methods
Serum samples were collected from the 593 blood donors
between July 2011 and October 2013, as reported previously.4
Serum samples were tested for the presence of immunoglobulin G
class antibodies (IgG) against each of the four DENV serotypes,
ZIKV, Japanese encephalitis virus (JEV), and West Nile virus (WNV)
by indirect ELISA,4 using recombinant antigens comprising domain
III of the envelope glycoprotein of each of the DENV-1, DENV-2,
DENV-3, DENV-4, ZIKV, JEV, and WNV strains5 (respective
GenBank accession numbers AF226686.1, FM986654, FJ44740.1,
FM986672.1, KJ776791, FJ979830, and AY033389).ciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
Table 1
Seropositivity for DENV, ZIKV, JEV, and WNV among blood donors in French
Polynesia (July 2011 to October 2013)
Blood donorsa
Group 1 Group 2 Group 3 Total
Number 132 290 171 593
Age, years
Range 18–59 18–69 19–75 18–75
Median 32 33 42 36
Time of residence in FP, years
Range 18–59 12–69 0–50 0–69
Median 32 32 12 27
Seropositivity for
At least one
DENV serotype
119 (90.2%) 260 (89.7%) 97 (56.7%) 476 (80.3%)
DENV-1 102 (77.3%) 219 (75.5%) 65 (38.0%) 386 (65.1%)
DENV-2 81 (61.4%) 158 (54.5%) 51 (29.8%) 290 (48.9%)
DENV-3 99 (75.0%) 205 (70.7%) 53 (31.0%) 357 (60.2%)
DENV-4 96 (72.7%) 195 (67.2%) 62 (36.3%) 353 (59.5%)
ZIKV 0 (0.0%) 5 (1.7%) 0 (0.0%) 5 (0.8%)
JEV 3 (2.3%) 5 (1.7%) 0 (0.0%) 8 (1.3%)
WNV 2 (1.5%) 6 (2.1%) 1 (0.6%) 9 (1.5%)
DENV, dengue virus; ZIKV, Zika virus; JEV, Japanese encephalitis virus; WNV, West
Nile virus; FP, French Polynesia.
a Group 1: residents who were born in French Polynesia and had never travelled
abroad; group 2: residents who were born in French Polynesia and had travelled
abroad at least once; group 3: immigrants.
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Among the 593 blood donors, 132 were born in French
Polynesia and had never travelled abroad (group 1), 290 were
born in French Polynesia and had travelled abroad at least once
(group 2), and 171 were immigrants (group 3). The age of these
blood donors ranged from 18 to 75 years (median 36 years) and the
duration of residence in French Polynesia ranged from 0 to 69 years
(median 27 years) (Table 1).
The overall seropositivity rates were 80.3% for at least one
DENV serotype, 0.8% for ZIKV, 1.3% for JEV, and 1.5% for WNV.
For DENV, the seropositivity rates were signiﬁcantly higher for
blood donors born in French Polynesia (90.2% in group 1 and 89.7%
in group 2) than for immigrants (56.7%) (median time of residence
in French Polynesia 32 and 12 years, respectively) (Fisher’s test,
p < 0.0001). Whatever the blood donor group, the highest
seropositivity rate was found for DENV-1 and the lowest for
DENV-2.
4. Discussion
In French Polynesia, with the exception of RRV and CHIKV,4 only
old data on the prevalence of arboviruses have been available and
these have exclusively concerned DENV. A serosurvey conducted
in 1987 showed that seropositivity rates for at least one DENV
serotype ranged from 7.4% in children aged less than 5 years to
83.1% in those aged 15–19 years, and increased with age.6 In the
present study, 80.3% of blood donors were found to be seropositive
for at least one DENV serotype. The successive outbreaks due to the
four DENV serotypes recorded in French Polynesia since the mid-
twentieth century1,7 may have contributed to the high seropreva-
lence found among blood donors aged 18 to 75 years. Not
surprisingly, a lower DENV seropositivity rate was found among
immigrants compared to blood donors born in French Polynesia,
with respective median durations of residence in French Polynesia
of 12 and 32 years, conﬁrming that DENV seroprevalence increases
with time spent in French Polynesia. The ﬁnding of the highest
seropositivity rate for DENV-1 and the lowest for DENV-2 is
consistent with epidemiological data recorded in French Polynesia.DENV-1 had been circulating for several years (2001–2009) and re-
emerged during the sampling period in March 2013,1,7 which may
explain the high proportion of blood donors seropositive for this
serotype. In contrast, the last circulation of DENV-2 was reported
12 years before the beginning of the study.1 The low level of herd
immunity against DENV-2 is associated with the risk of a large
outbreak if this serotype is introduced into French Polynesia.
Blood samples tested in this study were collected before the
emergence of ZIKV and CHIKV in French Polynesia.2,3 A small
proportion of blood donors had IgG against ZIKV (0.8%) and CHIKV
(3.0%).4 The large magnitude of both ZIKV and CHIKV epidemics in
French Polynesia in 2013 and 2014 could be explained by the low
levels of pre-existing immunity against these pathogens in the
population. Moreover, the low seroprevalence rates (1.5%)
against JEV and WNV suggest the absence of past active circulation
of these viruses in French Polynesia.
The herd immunity of a population is one of the factors to take
into account when evaluating the potential emergence of
arboviruses.8 Some prevention measures, such as mosquito bite
prevention and integrated vector management, are common for all
arboviruses. For other arboviruses such as JEV, speciﬁc measures
including vaccination are available.8 For DENV, future tetravalent
vaccines may have different efﬁcacy against the four serotypes.9
In the context of active circulation and new emergences of
arboviruses in the Paciﬁc,7 and the presence of several potential
mosquito vectors,10 information provided by this study may be
useful for public health authorities to improve surveillance and
implement strategies to prevent the transmission of arboviruses in
French Polynesia.
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